AppThera
AppThera is a French DTx prescription platform that lets physicians search a curated directory of clinically validated, CE/FDA-marked digital therapeutics and prescribe them to patients via RPPS/CPS authentication, with automated activation and PECAN insurance billing, monetizing via manufacturer commissions and institutional deployment services.
- Company typePrivate
- Founded2023
- HeadquartersParis, France
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What AppThera does
AppThera SAS is a French digital therapeutics (DTx) prescription platform, headquartered in Gentilly (Paris) and operating as a project under parent company Agora Health. Founded in 2023 to coincide with the opening of France's PECAN reimbursement pathway, the company provides a web-based directory of clinically validated DTx applications (CE-marked or FDA-approved, with RCT evidence) that physicians can search by indication and prescribe to patients in a single click via RPPS/CPS card authentication. Distributed DTx products on the platform span chronic pain (QoLibri), tinnitus (Oto), low back pain (SelfBack), diabetes (DiappyMed/EkiYou), smoking cessation (Quitoxil), endometriosis (Lyv Endo), obesity (Wellapy), and insomnia (HelloBetter), with several additional German-reimbursed DiGA products referenced for cross-market comparison.
The underlying technology is a cloud-hosted prescription stack (Scalingo, OVH France) integrating ProSanté Connect for prescriber identity, Brevo for automated patient SMS/email activation, Stripe for payment processing, and automated billing into the French PECAN reimbursement framework (60% Assurance Maladie, 40% mutuelles). The platform also exposes a manufacturer dashboard for prescription analytics, revenue tracking, and cash-flow forecasting, and offers professional-services deployment and training for healthcare institutions (CHU, CH, clinics, MSP).
Commercially, AppThera is a B2B2C marketplace that is free for prescribers and patients within the French PECAN pathway, and monetizes via commission on billed prescriptions paid by DTx manufacturers, plus professional-services fees for institutional deployment. The company has assembled a partnership ecosystem spanning the national health insurance administrator (CNAM), the largest French mutual insurer (MGEN), the largest hospital system in Europe (AP-HP), regional physician networks (URPS NAQ, Réseau Morphée), a teleconsultation platform (Livi), and outpatient clinic networks (ipso), positioning itself as the regulated prescription and distribution conduit between French prescribers and the reimbursed DTx formulary.
AppThera firmographics
Firmographics- Name
- AppThera
- Legal name
- APPTHERA SAS
- Website
- https://appthera.fr
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- AppThera is a French DTx prescription platform that lets physicians search a curated directory of clinically validated, CE/FDA-marked digital therapeutics and prescribe them to patients via RPPS/CPS authentication, with automated activation and PECAN insurance billing, monetizing via manufacturer commissions and institutional deployment services.
- Ownership category
- akta.pro rank
AppThera industry classification
Industry- Product category
- Digital Therapeutics Prescription Platform
- NAICS
- Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds (524292)
- SIC
- Services-Health Services (8000)
- akta.pro primary industry
- Prescription Digital Therapeutics (PDT) (HLACANAB)
- akta.pro secondary industries
- Pharmacy/Medication Management & Virtual MTM (Payer-Sponsored) (HLALACAK), Medication Adherence & Therapy Management Platforms (refills, reminders, MTM) (HLALAIAG)
Keywords
Where AppThera is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
AppThera business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Marketplace / Distribution commission: Commission fee on prescriptions billed through the platform. AppThera acts as a prescription and distribution intermediary between physicians, patients, and DTx manufacturers, charging a commission on each billed prescription.
- Patient distribution and activation services: AppThera distributes activation codes to patients on behalf of DTx manufacturers (both free prescriptions under PECAN and paid apps via the AppThera storefront). Takes a commission on paid applications sold through the platform.
- Health institution deployment and training: Provides deployment, integration, and training services for healthcare institutions (CHU, CH, clinics, MSP) that want to adopt DTx at scale. For CHU-level institutions (400,000+ consultations), a multidisciplinary integration and training team is deployed.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Free | Free for healthcare professionals |
| Transaction based/ take rate | Pay-as-you-go | Commission fee for DTx manufacturers |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels7 records
AppThera product offering
Product offeringCore offering
AppThera operates a web-based prescription platform that enables French healthcare professionals to search a curated directory of clinically validated digital therapeutics (DTx) and prescribe them to patients in a single click. The platform handles authenticated prescriber access via RPPS/CPS card, automated patient activation through SMS/email, and insurance billing under the French PECAN reimbursement framework. DTx manufacturers are onboarded as distribution partners, with AppThera taking a commission on billed prescriptions while providing manufacturers with a prescription analytics dashboard.
Product overview
AppThera operates as a prescription platform and distribution service for clinically validated digital therapeutics (DTx). The core AppThera Platform provides healthcare professionals with a curated directory (annuaire) of DTx applications that have demonstrated clinical benefit through RCT studies, one-click prescription functionality, and patient management dashboards. The platform distributes multiple branded DTx products across various therapeutic areas including chronic pain (QoLibri), tinnitus (Oto), low back pain (SelfBack), diabetes management (DiappyMed/EkiYou), smoking cessation (Quitoxil), endometriosis (Lyv Endo), obesity (Wellapy), and insomnia (HelloBetter Insomnie), among others. AppThera also provides a separate Professional Healthcare Portal for prescriber authentication via RPPS/CPS and a Patient Distribution Service handling activation codes, device delivery, and payment collection.
Differentiator
Problem solved
Functional benefit
Products and services
- AppThera Platform A web-based SaaS platform enabling French healthcare professionals to search, prescribe, and manage clinically validated digital therapeutics (DTx) to patients. Includes a curated DTx directory, one-click prescription workflow, patient onboarding via SMS/email, and a prescriber dashboard with insurance billing automation under the PECAN framework.
- QoLibri A digital therapeutic for chronic pain management using ACT and CBT approaches, integrating psychoeducation, emotional management, mindfulness, relaxation, breathing techniques, and progressive movement through yoga or tai-chi. Distributed via AppThera prescription in France.
- Oto A CE-marked cognitive behavioral therapy (CBT) application for tinnitus (acouphènes), prescribed as a complement to clinical consultations with 10-minute sessions. Distributed via AppThera prescription in France.
- SelfBack A digital therapeutic developed in Denmark for low back pain (lombalgie), providing tailored exercise programs and behavioral support. Distributed via AppThera prescription in France.
- DiappyMed (EkiYou) A French DTx from CHU Montpellier for diabetes management (Type 1 and Type 2 under basal-bolus regimen). Calculates personalized insulin doses based on glycemia, nutrition, and physical activity. Distributed via AppThera prescription in France.
- Quitoxil A smoking cessation digital therapeutic developed in collaboration with AP-HP Paul Brousse addictology department and INRIA. A randomized controlled study is planned for autumn 2025. Distributed via AppThera prescription in France.
- Lyv Endo A French CE-marked multidisciplinary digital therapeutic for endometriosis by Lyv, offering symptom tracking, therapeutic education, and lifestyle support. An RCT study is ongoing with partnerships with mutual insurance companies. Distributed via AppThera prescription in France.
- Wellapy A digital therapeutic for obesity (IMC > 30), covering nutritional tracking, therapeutic education, and physical activity guidance aligned with medical recommendations. Distributed via AppThera prescription in France.
- HelloBetter Insomnie A DTx for insomnia based on Charles Morin's model, featuring sleep hygiene, bed restriction, stimulus control, cognitive strategies, relaxation techniques, relapse prevention, and a permanent online sleep diary with human psychologist supervision. Distributed via AppThera in France.
Quantifiable outcome
- 38% of prescribed DTx patients use the app daily; 62% complete their full therapeutic program; 85% remain active after 30 days (vs. 8% for general wellness apps)
- +4 more outcomes
Companies that use AppThera
Customer profileNamed customers11 records
Segments5 records
Ideal customer profiles3 records
AppThera technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
Feature5 records
AppThera partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered minor and core.
- LiviminorLivi, a teleconsultation platform, partnered with AppThera for a joint webinar (June 12, 2024) where AppThera's co-founder and CEO Hélène Viatgé presented DTx to Livi's network of teleconsultation physicians. Livi provides the physician audience and platform for the joint educational event.
- Agora HealthcoreAppThera is a project by Agora Health, which operates as the parent organization. Agora Health is a digital health company focused on making validated health solutions accessible. AppThera isAgora Health's flagship platform for DTx prescription in the French market. Contact and DPO address ([email protected]) indicate Agora Health's governance role.
- URPS Médecins libéraux Nouvelle-Aquitaine (URPS NAQ)minorURPS NAQ (Union Régionale des Professionnels de Santé) is listed as a partner on AppThera's website. URPS bodies are regional professional health organizations that support and represent liberal healthcare professionals. The partnership likely supports outreach to regional physician networks.
- Assistance Publique - Hôpitaux de Paris (AP-HP)minorAP-HP is listed as a partner on AppThera's website. As France's largest hospital system, AP-HP represents a key channel for DTx adoption among hospital-based physicians and a reference institutional partner for DTx clinical validation.
- MGEN (Mutuelle Générale de l'Education Nationale)minorMGEN is listed as a partner on AppThera's website. MGEN is a major French mutual health insurance fund covering education sector employees. The partnership likely supports patient access to reimbursed DTx and mutual insurance billing integration.
- Caisse Nationale d'Assurance Maladie (CNAM)minorCNAM is listed as a partner on AppThera's website. CNAM is the national public health insurance fund of France. As the administrator of the PECAN reimbursement program, CNAM is a critical partner for automated billing of DTx prescriptions through AppThera.
- ipso (Réseau de cliniques ambulatoires)minoripso (Réseau de cliniques ambulatoires) is listed as a partner on AppThera's website. ipso operates a network of outpatient clinics in France. Partnership supports outreach to physicians practicing in the ipso clinic network for DTx prescription adoption.
- Réseau MorphéeminorRéseau Morphée is a French sleep health network. Dr Sandrine Launois-Rollinat, President of Réseau Morphée, prescribes DTx for insomnia through AppThera, indicating an active channel partnership for sleep-related DTx prescriptions.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
AppThera competitors and assessment
Company assessmentDirect peers
- Selfapy: German DTx platform offering prescription-grade digital therapeutic programs across multiple indications. Closely comparable to AppThera's model of curated, reimbursed DTx delivery, with analogous reimbursement pathway via DiGA.
- HealthHero: European digital health company combining teleconsultation, prescription, and chronic condition management. Operates a similar multi-channel digital care delivery model with prescriber integration comparable to AppThera's platform.
- HelloBetter: German DTx publisher and platform whose products (e.g., HelloBetter Insomnie) are already listed on AppThera. Operates the same digital therapeutics model under Germany's DiGA reimbursement framework, providing a direct cross-market comparison for AppThera's French PECAN approach.
- Sidekick Health: European digital therapeutics platform providing prescribed digital care programs for chronic conditions. Operates a similar prescription-enabled, condition-specific DTx model across multiple therapeutic areas comparable to AppThera's directory.
- Kaia Health: Digital therapeutics company offering prescribed apps for chronic pain and other conditions. Comparable to AppThera's distributed products (e.g., QoLibri) and to the broader prescription DTx model AppThera enables.
- Zava: European DTC telehealth platform offering online consultations with prescription services. Comparable to AppThera in combining digital consultation workflows with prescription issuance, though broader in scope beyond DTx.
- Livi: European teleconsultation platform partnered with AppThera for DTx education to its physician network. Both operate prescription-enabled digital health services in Europe and target physician workflows for digital care delivery.
Broad incumbents
- Doctolib: France's dominant health platform with millions of prescribers and broad practice management capabilities. Doctolib is a major potential competitor in DTx prescription infrastructure given its installed physician base, though it is not currently DTx-specialized.
- Maiia (Cegedim): French teleconsultation and practice management platform from Cegedim with physician scheduling and patient management. Comparable to AppThera in targeting French physician workflows and could expand into DTx prescription.
Others
- Tunstall Healthcare: European telehealth and remote patient monitoring provider with prescription-adjacent workflows. Adjacent to AppThera's prescription infrastructure play, focused more on chronic disease monitoring than DTx directory.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights6 records
Customer concentration
AppThera social profiles
Digital presenceAppThera compliance and trust
Trust signalCompliance4 records
AppThera financial estimates
Financial estimateRevenue estimate
Valuation estimate
AppThera leadership team
Management profileNumber of profiles
Profiles3 records
AppThera funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AppThera M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AppThera
What does AppThera do?
AppThera operates a web-based prescription platform that enables French healthcare professionals to search a curated directory of clinically validated digital therapeutics (DTx) and prescribe them to patients in a single click. The platform handles authenticated prescriber access via RPPS/CPS card, automated patient activation through SMS/email, and insurance billing under the French PECAN reimbursement framework. DTx manufacturers are onboarded as distribution partners, with AppThera taking a commission on billed prescriptions while providing manufacturers with a prescription analytics dashboard.
Is AppThera a public or private company?
AppThera is a private company. It is classified as corporate owned and is currently operating.
When was AppThera founded?
AppThera was founded in 2023. It employs 1 to 10 people.
Where is AppThera based?
AppThera is headquartered in Paris, France, in the Europe region.
How does AppThera make money?
Three revenue lines are on record. Marketplace / Distribution commission is the primary driver. The others are patient distribution and activation services and health institution deployment and training.
Who are AppThera's main competitors?
Direct peers on record are Selfapy, HealthHero, HelloBetter, Sidekick Health, Kaia Health, Zava and Livi. Broad incumbents are Doctolib and Maiia (Cegedim). Tunstall Healthcare is listed as an others.
Does AppThera have an API?
No public API is recorded for AppThera.
What industry is AppThera in?
AppThera's product category is Digital Therapeutics Prescription Platform. Its primary akta.pro industry code is HLACANAB, Prescription Digital Therapeutics (PDT), with a secondary code of HLALACAK, Pharmacy/Medication Management & Virtual MTM (Payer-Sponsored). Its NAICS code is 524292 and its SIC code is 8000.